Avenue Therapeutics, Inc.
ATXIOTCHealthcare● Active
$0.31
$-0.04(-12.06%)
Market Cap$1021440
P/E Ratio—
52W High$0.9699
52W Low$0.15
Avenue Therapeutics, Inc. (ATXI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATXI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.40M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $1.40M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $1.04M | $6.64M | $10.36M | $2.70M | $1.25M |
| G&A Expenses | $3.65M | $4.64M | $4.18M | $5.34M | $2.48M |
| Total Operating Expenses | $4.69M | $11.28M | $14.54M | $8.04M | $3.74M |
| Operating Income | ($3.29M) | ($11.28M) | ($14.54M) | ($8.04M) | ($3.74M) |
| Operating Margin %(computed) | -234.05% | — | — | — | — |
| Interest Income | $0.12M | $0.18M | $0.13M | $0.02M | $0.01M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $1.16M | $0.00M |
| Income Before Tax | ($2.95M) | ($11.70M) | ($10.49M) | ($3.60M) | ($3.73M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($2.91M) | ($11.65M) | ($10.38M) | ($3.55M) | ($3.73M) |
| Net Margin %(computed) | -207.19% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.93 | $-0.90 | $-73.60 | $-121.91 | $-3.29 |
| Wtd Avg Shares | 3.13M | 12.95M | 0.14M | 0.03M | 1.13M |
| EBITDA | ($3.29M) | ($11.70M) | $4.05M | ($2.44M) | $0.01M |
| EBITDA Margin %(computed) | -234.05% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Avenue Therapeutics, Inc. data
About Avenue Therapeutics, Inc. (ATXI) Income Statement
Avenue Therapeutics, Inc. (ATXI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ATXI reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -207.19%.
Frequently asked questions
ATXI · 4 questionsAvenue Therapeutics, Inc. (ATXI) reported revenue of $0.00B for 2025, up —% year-over-year.
ATXI revenueATXI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08